Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Jennifer V. Linseman"'
Autor:
Jennifer V. Linseman, Sarah Arterburn, Philip T. Sager, Henry R. Black, Lars H Lindholm, Henry Krum, George L. Bakris, Michael A. Weber, Stuart L. Linas
Publikováno v:
Hypertension. 56:824-830
Patients with resistant hypertension are at increased risk for cardiovascular events. The addition of new treatments to existing therapies will help achieve blood pressure (BP) goals in more resistant hypertension patients. In the current trial, 849
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cbf9cab97b26b0cbf47966d2d84dce81
https://doi.org/10.1161/hypertensionaha.110.156976
https://doi.org/10.1161/hypertensionaha.110.156976
Autor:
Brian L. Wiens, Jennifer V. Linseman, Marc Weber, Henry R. Black, Stuart L. Linas, Henry Krum, Lars H Lindholm, Warren, Robert G. Weiss, George L. Bakris
Publikováno v:
Journal of Human Hypertension. 23:687-707
Darusentan treatment significantly decreases blood pressure and results in better systolic blood pressure control when added to multi-drug therapy in patients with resistant hypertension
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::03e7f4d443f690851425bcb4223b9095
https://doi.org/10.1038/jhh.2009.69
https://doi.org/10.1038/jhh.2009.69
Publikováno v:
Therapy. 5:739-750
Darusentan is an ETA-selective endothelin receptor antagonist that is currently in Phase III clinical development for the treatment of resistant hypertension (RHTN). Current hypertension treatment guidelines describe RHTN as the failure to achieve go
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::972fbe91de44ea2b0ab4547021ea5362
https://doi.org/10.2217/14750708.5.6.739
https://doi.org/10.2217/14750708.5.6.739
Autor:
J. A. Lindenfeld, Robert L. Roden, Eugene E. Wolfel, Simon F. Shakar, Patti Larrabee, Edward M. Gilbert, Wayne Minobe, Debra A. Ferguson, Jennifer V. Linseman, Kirk Volkman, Brian D. Lowes, Darrin L. Dutcher, Michael R. Bristow, Alastair D. Robertson, James H Sederberg, Robert A. Quaife, William T. Abraham
Publikováno v:
Molecular Medicine. 8:750-760
BACKGROUND: The most common cause of chronic heart failure in the US is secondary or primary dilated cardiomyopathy (DCM). The DCM phenotype exhibits changes in the expression of genes that regulate contractile function and pathologic hypertrophy. Ho
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eb1703eecdcd99429032ae94261e30aa
https://doi.org/10.1007/bf03402039
https://doi.org/10.1007/bf03402039
Publikováno v:
Circulation. 107:1234-1236
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6c0ea9c1b0dba96363ef2489463ec6a5
https://doi.org/10.1161/01.cir.0000056033.16159.48
https://doi.org/10.1161/01.cir.0000056033.16159.48
Autor:
Brian L. Wiens, Jennifer V. Linseman, Michael A. Weber, Robert G. Weiss, Marshelle Warren, Henry R. Black, Henry Krum, Stuart L. Linas, George L. Bakris, Lars H Lindholm
Publikováno v:
Lancet (London, England). 374(9699)
Hypertension cannot always be adequately controlled with available drugs. We investigated the blood-pressure-lowering effects of the new vasodilatory, selective endothelin type A antagonist, darusentan, in patients with treatment-resistant hypertensi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b343b49eec7ea7f7593af35cd5cd341
https://pubmed.ncbi.nlm.nih.gov/21043838
https://pubmed.ncbi.nlm.nih.gov/21043838
Autor:
Henry R. Black, Georges Tannoury, Jennifer V. Linseman, Mahfouz El Shahawy, George L. Bakris, Robert J. Weiss, Brian L. Wiens, Richard Marple, Stuart L. Linas, Robert Roden, Michael A. Weber, Michael J. Gerber
Publikováno v:
J Clin Hypertens (Greenwich)
In this phase 2, randomized, double-blind, placebo-controlled forced dose-titration study, 115 patients with resistant hypertension, receiving background therapy with >/=3 antihypertensive medications including a diuretic at full doses, were randomiz
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ffd3bf2fc70f05a9b13fc6d4bf4c6a8
https://pubmed.ncbi.nlm.nih.gov/17917503
https://pubmed.ncbi.nlm.nih.gov/17917503
Autor:
Jean Francois Liard, Simon F. Shakar, Jennifer V. Linseman, J. William Freytag, Ellen B. Roecker, Marco Metra, Michael R. Bristow, Alastair D. Robertson, Jennifer Stewart, Brian D. Lowes, Arthur M. Feldman, Craig Hartman, Gwyn Evans, David L. DeMets, Rick Gorczynski, Eric J. Eichhorn, Michael J. Gerber
Publikováno v:
Journal of cardiac failure. 11(9)
Background Chronic heart failure is a disease syndrome characterized in its advanced stages by a poor quality of life, frequent hospitalizations, and a high risk of mortality. In advanced and ultra-advanced chronic heart failure, many treatment optio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::58b7b4a37a30b841c9b116c6ab80c73f
https://pubmed.ncbi.nlm.nih.gov/16360960
https://pubmed.ncbi.nlm.nih.gov/16360960
Publikováno v:
Journal of cardiac failure. 7(2 Suppl 1)
Beta-adrenergic blocking agents are standard treatment for patients with mild-to-moderate heart failure. When patients receiving beta-blockers decompensate they often need treatment with a positive inotropic agent. The beta-agonist dobutamine may not
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5af07ed46256035ee71fe1e5a3aad422
https://pubmed.ncbi.nlm.nih.gov/11605160
https://pubmed.ncbi.nlm.nih.gov/11605160
Publikováno v:
The Lancet. 375:636-637
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b3b1149d6bc21b72dce7b902fbb6b53b
https://doi.org/10.1016/s0140-6736(10)60263-2
https://doi.org/10.1016/s0140-6736(10)60263-2